Stage 3 breast cancer treatment almost always involves a combination of therapies, typically starting with chemotherapy to shrink the tumor before surgery, followed by radiation and long-term medications tailored to the specific biology of the cancer. Nearly every person with a stage 3 diagnosis will need at least two or three of these treatments working together. The exact plan depends on the cancer’s subtype, meaning whether it’s fueled by hormones, a protein called HER2, or neither.
Why Chemotherapy Usually Comes First
In stage 3 breast cancer, chemotherapy is most often given before surgery. This approach, called neoadjuvant chemotherapy, has a specific purpose: shrink the tumor and reduce cancer in the lymph nodes so that surgery can be more effective and, in some cases, less extensive. For cancers that are initially too large or too involved with surrounding tissue to operate on safely, upfront chemotherapy can make surgery possible.
Standard chemotherapy regimens typically include two classes of drugs, anthracyclines and taxanes, given in sequence. A common schedule involves four cycles of one combination followed by 12 weekly doses of another, stretching the total chemotherapy timeline to roughly 20 to 24 weeks. Some protocols compress this into a different cycle pattern, but the overall duration is similar. How well the tumor responds to this pre-surgery chemotherapy gives your oncology team important information. If the tumor disappears entirely on pathology after surgery (called a pathological complete response), that’s a strong positive sign for long-term outcomes.
Surgery: Mastectomy vs. Lumpectomy
After chemotherapy, the next step is surgery to remove the remaining cancer. At stage 3, mastectomy (removal of the entire breast) is far more common. In one large survey of stage 3 patients, about 81% had a mastectomy compared to roughly 19% who had a lumpectomy (removal of just the tumor and a margin of surrounding tissue).
Mastectomy is more likely when the cancer involves multiple areas of the breast, when the tumor is large relative to breast size, or when there’s a genetic mutation that raises the risk of future cancers. Lumpectomy may still be an option if chemotherapy significantly shrinks the tumor and the remaining cancer is small enough to remove with clear margins. The choice also reflects personal preference, since some people prioritize breast conservation while others prefer the certainty of removing the whole breast.
Regardless of which surgery you have, surgeons typically remove and examine lymph nodes under the arm to check for cancer spread. This lymph node removal is an important part of staging and treatment, though it does carry a risk of long-term arm swelling called lymphedema.
Radiation After Surgery
Radiation is standard after surgery for stage 3 breast cancer. After mastectomy, radiation targets the chest wall and the surrounding lymph node areas, including nodes under the arm, above the collarbone, and near the breastbone. After lumpectomy, radiation covers the remaining breast tissue along with the same lymph node regions.
The benefit is clearest for people with cancer found in four or more lymph nodes. A large pooled analysis found that post-mastectomy radiation in this group reduced the risk of cancer coming back locally by 19%, which translated into a 9% reduction in breast cancer death. For those with one to three positive nodes, radiation is strongly considered but weighed against individual factors like age, tumor size, and tumor grade. Radiation typically runs daily for several weeks, though shorter schedules have become more common.
Treatment Tailored to Cancer Subtype
After surgery and radiation address the local disease, long-term systemic therapy depends on the molecular profile of your cancer. This is where the three main subtypes diverge significantly.
Hormone Receptor-Positive Cancer
If the cancer tests positive for estrogen or progesterone receptors, hormone therapy is a core part of treatment. These medications block the hormones that fuel cancer growth. Depending on whether you’re pre- or post-menopausal, options include tamoxifen, aromatase inhibitors, or one followed by the other. Hormone therapy is taken daily as a pill and continues for at least five years, with some people staying on it for up to ten years based on their risk of recurrence. This is one of the longest commitments in the treatment plan, but it substantially reduces the chance of cancer returning.
HER2-Positive Cancer
About 15 to 20% of breast cancers overproduce a protein called HER2 that drives aggressive growth. For these cancers, targeted drugs are added to chemotherapy both before and after surgery. Trastuzumab, the foundational HER2-targeting drug, is typically given alongside pertuzumab for tumors larger than 2 cm. These are administered by infusion and continue for up to a year total. If cancer remains after neoadjuvant chemotherapy and surgery, a different targeted drug called trastuzumab emtansine (T-DM1) may replace standard trastuzumab in the post-surgery phase. The addition of HER2-targeted therapy has dramatically improved outcomes for this subtype over the past two decades.
Triple-Negative Cancer
Triple-negative breast cancer doesn’t respond to hormone therapy or HER2-targeted drugs, which historically left chemotherapy as the only systemic option. That changed with the addition of immunotherapy. The KEYNOTE-522 trial, published in the New England Journal of Medicine, showed that adding the immunotherapy drug pembrolizumab to chemotherapy before surgery, then continuing it after surgery for up to nine additional cycles, significantly improved survival. At five years, 86.6% of patients who received immunotherapy plus chemotherapy were alive compared to 81.7% who received chemotherapy alone. Immunotherapy is now part of the standard treatment approach for stage 2 and stage 3 triple-negative breast cancer.
Breast Reconstruction Timing
For people who have a mastectomy and want reconstruction, the timing can be complicated by the need for post-surgery radiation. Reconstruction done before radiation risks complications and changes to the aesthetic result as radiation can cause tissue to tighten and scar. For this reason, many surgical teams have traditionally recommended waiting until radiation is complete, which can mean months before reconstruction begins.
More recent evidence, however, suggests that immediate reconstruction using your own tissue (rather than implants) may produce comparable long-term results even when followed by radiation. The decision involves balancing your priorities, your anatomy, and input from the surgical oncologist, plastic surgeon, and radiation oncologist together. There is no single right answer, and the best approach is the one that fits your specific situation and treatment timeline.
What the Full Treatment Timeline Looks Like
From start to finish, active treatment for stage 3 breast cancer typically spans six months to a year or more. Neoadjuvant chemotherapy takes roughly five to six months. Surgery and recovery add several weeks. Radiation runs for a few weeks after surgical healing. Targeted therapy or immunotherapy infusions may continue for up to a year after surgery. And hormone therapy, if applicable, extends for five to ten years beyond that.
The intensity is front-loaded. The chemotherapy and surgery phase is the most physically demanding, with side effects like fatigue, nausea, hair loss, and immune suppression. Radiation brings localized skin irritation and fatigue. The longer-term medications, whether hormone therapy, targeted therapy, or immunotherapy, carry their own side effects but are generally more manageable in daily life. Many people return to work and normal routines during the post-surgery treatment phase, though the timeline varies widely from person to person.